These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36562410)

  • 1. The Promising Therapeutic Potential of Oligonucleotides for Pulmonary Fibrotic Diseases.
    Paul D; Miller MH; Born J; Samaddar S; Ni H; Avila H; Krishnamurthy VR; Thirunavukkarasu K
    Expert Opin Drug Discov; 2023 Feb; 18(2):193-206. PubMed ID: 36562410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations of the Japanese Research Working Group for the ICH S6 & Related Issues Regarding Nonclinical Safety Assessments of Oligonucleotide Therapeutics: Comparison with Those of Biopharmaceuticals.
    Hirabayashi Y; Maki K; Kinoshita K; Nakazawa T; Obika S; Naota M; Watanabe K; Suzuki M; Arato T; Fujisaka A; Fueki O; Ito K; Onodera H
    Nucleic Acid Ther; 2021 Apr; 31(2):114-125. PubMed ID: 33470890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.
    Willis L; Hayes D; Mansour HM
    Lung; 2012 Jun; 190(3):251-62. PubMed ID: 22274758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs).
    Bano N; Ehlinger C; Yang TY; Swanson M; Allen S
    AAPS J; 2022 Aug; 24(5):93. PubMed ID: 36028587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases.
    Liao W; Dong J; Peh HY; Tan LH; Lim KS; Li L; Wong WF
    Molecules; 2017 Jan; 22(1):. PubMed ID: 28106744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics.
    Ramsden D; Belair DG; Agarwal S; Andersson P; Humphreys S; Dalmas DA; Stahl SH; Maclauchlin C; Cichocki JA
    ALTEX; 2022; 39(2):273–296. PubMed ID: 34766620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery.
    Zimmermann CM; Baldassi D; Chan K; Adams NBP; Neumann A; Porras-Gonzalez DL; Wei X; Kneidinger N; Stoleriu MG; Burgstaller G; Witzigmann D; Luciani P; Merkel OM
    J Control Release; 2022 Nov; 351():137-150. PubMed ID: 36126785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patented therapeutic drug delivery strategies for targeting pulmonary diseases.
    Thakur AK; Chellappan DK; Dua K; Mehta M; Satija S; Singh I
    Expert Opin Ther Pat; 2020 May; 30(5):375-387. PubMed ID: 32178542
    [No Abstract]   [Full Text] [Related]  

  • 10. The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders?
    Ye Y; Ma Y; Zhu J
    Int J Pharm; 2022 Feb; 614():121457. PubMed ID: 35026316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher lung accumulation of intravenously injected organic nanotubes.
    Maitani Y; Nakamura Y; Kon M; Sanada E; Sumiyoshi K; Fujine N; Asakawa M; Kogiso M; Shimizu T
    Int J Nanomedicine; 2013; 8():315-23. PubMed ID: 23345977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation techniques for high dose dry powders.
    Brunaugh AD; Smyth HDC
    Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSP47: a potential target for fibrotic diseases and implications for therapy.
    Bellaye PS; Burgy O; Bonniaud P; Kolb M
    Expert Opin Ther Targets; 2021 Jan; 25(1):49-62. PubMed ID: 33287600
    [No Abstract]   [Full Text] [Related]  

  • 14. Dry powder inhalers for pulmonary drug delivery.
    Frijlink HW; De Boer AH
    Expert Opin Drug Deliv; 2004 Nov; 1(1):67-86. PubMed ID: 16296721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligonucleotide-targeting periostin ameliorates pulmonary fibrosis.
    Tomaru A; Kobayashi T; Hinneh JA; Baffour Tonto P; D'Alessandro-Gabazza CN; Fujimoto H; Fujiwara K; Takahashi Y; Ohnishi M; Yasuma T; Nishihama K; Yoshino M; Takao K; Toda M; Totoki T; Takei Y; Yoshikawa K; Taguchi O; Gabazza EC
    Gene Ther; 2017 Nov; 24(11):706-716. PubMed ID: 28820502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology-Assisted Metered-Dose Inhalers (MDIs) for High-Performance Pulmonary Drug Delivery Applications.
    Kumar R; Mehta P; Shankar KR; Rajora MAK; Mishra YK; Mostafavi E; Kaushik A
    Pharm Res; 2022 Nov; 39(11):2831-2855. PubMed ID: 35552983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung-targeted delivery of TGF-β antisense oligonucleotides to treat pulmonary fibrosis.
    Kim J; Jeon S; Kang SJ; Kim KR; Thai HBD; Lee S; Kim S; Lee YS; Ahn DR
    J Control Release; 2020 Jun; 322():108-121. PubMed ID: 32179111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phytoconstituent based dry powder inhalers as biomedicine for the management of pulmonary diseases.
    Mehta P; Bothiraja C; Mahadik K; Kadam S; Pawar A
    Biomed Pharmacother; 2018 Dec; 108():828-837. PubMed ID: 30372894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
    Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
    J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary delivery of anti-inflammatory agents.
    Ali ME; McConville JT; Lamprecht A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):929-45. PubMed ID: 25534260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.